ArticleIntractable & rare diseases research2017
Defining rare diseases in China.
Article in Intractable & rare diseases research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- From presence to provenance: Building substantive infrastructure for China's rare disease ecosystem.Intractable & rare diseases research · 2026Review
- Long-term distress throughout one's life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in China.Frontiers in public health · 2024Article
- How will the public health committees develop after COVID-19 pandemic in China? Exploration from mixed methods study in Pingshan District, Shenzhen.Frontiers in public health · 2024Article
- Is sub-national healthcare social protection sufficient for protecting rare disease patients? the case of China.Frontiers in public health · 2023Review
- National Rare Diseases Registry System (NRDRS): China's first nation-wide rare diseases demographic analyses.Orphanet journal of rare diseases · 2021Article
- Demographics, in-hospital analysis, and prevalence of 33 rare diseases with effective treatment in Shanghai.Orphanet journal of rare diseases · 2021Article
- Establishing a rare diseases center: Experiences from Western China.Intractable & rare diseases research · 2021Article
- Determining the Topic Evolution and Sentiment Polarity for Albinism in a Chinese Online Health Community: Machine Learning and Social Network Analysis.JMIR medical informatics · 2020Article
- Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.European journal of human genetics : EJHG · 2020Article
- Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai.Orphanet journal of rare diseases · 2019Article
- Health service security of patients with 8 certain rare diseases: evidence from China's national system for health service utilization of patients with healthcare insurance.Orphanet journal of rare diseases · 2019Article
- A compilation of national plans, policies and government actions for rare diseases in 23 countries.Intractable & rare diseases research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
China has the world's largest population of people with rare diseases. However, defining rare diseases remains a challenge in China. Over the past few decades, several definitions have been proposed but they have yet to be agreed to by all stakeholders. To overcome this impasse, a list of several rare diseases has recently been created. This rare disease list might be used in place of a prevalence-based definition, especially in healthcare policy-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.